Today: 9 June 2026
Browse Category

NASDAQ:PAYC 10 July 2025 - 28 March 2026

Paycom Stock Slides 5% as Software Selloff Intensifies, 2026 Growth Worries Linger

Paycom Stock Slides 5% as Software Selloff Intensifies, 2026 Growth Worries Linger

Paycom Software shares dropped 4.85% to $117.06 on Friday, outpacing declines in the S&P 500 and Nasdaq. The selloff followed last month’s weak 2026 revenue outlook, which remains below analyst forecasts. Director Archana Vemulapalli will leave the board March 31, according to an SEC filing. Paycom’s market value closed at about $12.0 billion.
28 March 2026
···
Lumentum Holdings Stock Jumps as S&P 500 Addition Extends Nvidia-Linked AI Optics Rally (News Release Archive)

Lumentum Holdings Stock Jumps as S&P 500 Addition Extends Nvidia-Linked AI Optics Rally (News Release Archive)

Lumentum shares rose 10.6% to $617.81 in New York trading after S&P Dow Jones Indices said it will add the company to the S&P 500 on March 23. The move follows Nvidia’s $2 billion investment and a multiyear purchase agreement announced last week. Peers Coherent and Vertiv also gained. Lumentum reported second-quarter revenue up 65.5% to $665.5 million and forecast third-quarter revenue of up to $830 million.
9 March 2026
···········
Global HCM Software Market Update (June–July 2025) – Key Trends, News & Forecasts

Global HCM Software Market Update (June–July 2025) – Key Trends, News & Forecasts

The global HR/HCM and payroll software market is projected to reach $57.8 billion by 2029 and $91.7 billion by 2034, growing about 10% annually. North America holds 36% of revenue, while Asia-Pacific leads in growth at 12% CAGR. The top 10 vendors account for just 10% of 2023 revenue. A surge in AI product launches in mid-2025 prompted a 45% annual growth forecast for AI-powered HR agents.
10 July 2025
········

Stock Market Today

  • Jim Cramer's Top 10 Market Watch Points for June 9
    June 9, 2026, 9:57 AM EDT. Jim Cramer's top 10 things to watch on June 9 include U.S. stocks rebounding after a selloff, supported by lower oil prices and bond yields. The SpaceX IPO is heavily oversubscribed, expected to start trading Friday, while OpenAI filed confidentially for its IPO with a potential trillion-dollar valuation. Anthropic secured a $35 billion debt deal to fund its AI growth. TD Cowen raised its Alphabet price target to $475 amid margin optimism, despite dilution concerns. Amazon issued a $10 billion Canadian dollar bond, the largest in that currency. China plans to invest $295 billion in AI data centers over five years. Micron is expected to beat earnings guidance, while Apple shares face pressure despite AI enhancements. GSK's $10.6 billion acquisition of Nuvalent lifts shares, highlighting moves in the healthcare sector.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop